| Celgene Pays US$710 M Upfront to License Nogra Pharma’s Phase III-Ready GED-0301 |
Abstract
|
|
Heather Cartwright |
|
| Roche Partners with Oryzon Genomics and Spero Therapeutics |
Abstract
|
|
Heather Cartwright |
|
| Baxter Strengthens Haemophilia Franchise with Chatham Therapeutics Purchase as Biogen Enters Market |
Abstract
Untitled
|
|
Heather Cartwright |
|
| Sun Pharma Agrees to Buy Struggling Ranbaxy from Daiichi Sankyo in US$4 B Deal |
Abstract
|
|
Heather Cartwright |
|
| Mallinckrodt Expands Speciality Pharmaceuticals Business with US$5.6 B Questcor Acquisition |
Abstract
|
|
Heather Cartwright |
|
| Novartis and GSK Shift M&A Paradigm with Trio of Deals |
Abstract
|
|
Heather Cartwright |
|
| BioAlliance Pharma and Topotarget Agree to Merge and Combine Late-State Orphan Oncology Assets |
Abstract
|
|
Heather Cartwright |
|
| Forest Expands Gastrointestinal Portfolio with up to US$1.46 B Furiex Purchase |
Abstract
|
|
Heather Cartwright |
|
| BMS Buys iPierian and its Anti-Tau Programme for a Potential US$725 M |
Abstract
|
|
Heather Cartwright |
|
| Bayer Wins Auction for Merck & Co.’s OTC Business and Offers Cardiovascular Disease Collaboration Sweetener |
Abstract
|
|
Heather Cartwright |
|
